Results 31 to 40 of about 281,748 (215)

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

All we know about polycythemia vera: literature review and own experience

Онкогематология, 2015
The literature review and own long-term polycythemia vera diagnosis and treatment experience are presented in this article. The results of newest advances in pathogenesis description, modern diagnostic techniques and treatment modalities in polycythemia ...
K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source

A case of CALR mutation in JAK2-negative patient with polycythemia

Онкогематология, 2022
JAK2 mutations can be associated with any phenotypic form of chronic myeloproliferative neoplasia, while MPL and CALR mutations occur, as a rule, in cases of essential thrombocythemia and primary myelofibrosis and they are not observed in polycythemia ...
T. N. Subbotina, I. E. Maslyukova, D. V. Kurochkin, M. A. Mikhalev, M. G. Osadchaya, V. A. Khorzhevskiy, T. A. Garkusha, E. A. Dunaeva, K. O. Mironov   +8 more
doaj   +1 more source

Hereditary hemochromatosis and JAK2‐positive polycythemia vera

Clinical Case Reports, 2021
A 59‐year‐old man was diagnosed with JAK2‐positive polycythemia vera. Subsequently, further laboratory testing revealed elevated ferritin and iron saturation.
Ahmed Radwan, Ibraheem Othman
doaj   +1 more source

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.

Blood, 2020
There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately utilize repeated ...
L. Ronner, N. Podoltsev, J. Gotlib, M. Heaney, A. Kuykendall, C. O'Connell, J. Shammo, Angela G. Fleischman, R. Scherber, R. Mesa, A. Yacoub, C. Perkins, S. Meckstroth, Lindsey Behlman, M. Chiaramonte, M. Salehi, Kimia Ziadkhanpour, Hellen Nguyen, Olivia Siwoski, A. Hung, M. Janania Martinez, Jenny Nguyen, Sagar V. Patel, R. Kollipara, Ami Dave, M. Randall, Mike Grant, M. Harrison, Paola Fernandez Soto, D. Tremblay, R. Hoffman, E. Moshier, J. Mascarenhas   +32 more
semanticscholar   +1 more source

Double Thrombosis- Interesting Case of Polycythemia Vera [PDF]

Journal of Clinical and Diagnostic Research, 2020
Polycythemia vera is a myeloproliferative disorder which has a varied manifestation, one of it being venous thrombosis and arterial thrombosis which significantly contributes to the mortality and morbidity.
Subashini Subramanian, Siva Ranganathan Green   +1 more
doaj   +1 more source

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

Blood Advances, 2020
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is ...
A. Masciulli, A. Ferrari, A. Carobbio, A. Ghirardi, T. Barbui   +4 more
semanticscholar   +1 more source

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy

International Journal of Molecular Sciences, 2020
Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic progression and/or leukemic evolution over time.
A. Iurlo, D. Cattaneo, C. Bucelli, L. Baldini   +3 more
semanticscholar   +1 more source

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

Haematologica, 2009
Background The JAK2V617F mutation has been associated with constitutive and enhanced activation of neutrophils, while no information is available concerning other leukocyte subtypes.Design and Methods We evaluated correlations between JAK2V617F mutation ...
Lisa Pieri, Costanza Bogani, Paola Guglielmelli, Maria Zingariello, Rosa Alba Rana, Niccolò Bartalucci, Alberto Bosi, Alessandro M. Vannucchi   +7 more
doaj   +1 more source

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

Leukemia, 2020
Rambaldi, A., Iurlo, A., Vannucchi, A. M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M. F., Cambier, N., Marolleau, J-P., Mesa, R. A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica,
A. Rambaldi, A. Iurlo, A. Vannucchi, R. Noble, N. von Bubnoff, A. Guarini, B. Martino, A. Pezzutto, G. Carli, M. De muro, Stefania Luciani, M. McMullin, N. Cambier, J. Marolleau, R. Mesa, R. Tibes, A. Pancrazzi, F. Gesullo, P. Bettica, Sara Manzoni, Silvia Di Tollo   +20 more
semanticscholar   +1 more source